Compugen (CGEN)

History and Background

Compugen was founded in 1993. Initially focused on computational drug discovery, it has evolved into a clinical-stage drug discovery and development company focused on immuno-oncology.

Core Business Areas

• Immuno-Oncology: Compugen focuses on discovering and developing novel therapeutics that harness the immune system to fight cancer, particularly targeting previously undiscovered drug targets within the tumor microenvironment.

Leadership and Structure

Compugen is led by a CEO and has a board of directors. The company's structure includes research and development, clinical development, and business development teams.

Key Offerings

• COM701: COM701 is a first-in-class antibody targeting PVRIG, a novel immune checkpoint target. It is in clinical development for various solid tumors. No specific market share data is available. Competitors include companies developing checkpoint inhibitors.
• BAY 1905254 (formerly COM902): BAY 1905254 (formerly COM902) is a monoclonal antibody targeting TIGIT. Bayer is developing this product under a licensing agreement with Compugen. No specific market share data is available. Competitors include companies developing TIGIT inhibitors.

Industry Overview

The immuno-oncology market is a rapidly growing segment of the pharmaceutical industry, driven by the increasing prevalence of cancer and the potential of immunotherapy to provide durable responses. It is highly competitive.

Positioning

Compugen is positioned as an innovator in the immuno-oncology space, focused on discovering and developing first-in-class therapies targeting novel immune checkpoints. Its competitive advantage lies in its target discovery platform.

Total Addressable Market (TAM)

The total addressable market for immuno-oncology is estimated to be in the tens of billions of dollars. Compugen is positioned to capture a portion of this market through its innovative pipeline.

Key Competitors

• BMY
• MRK
• PFE
• AZN
• GILD

Competitive Landscape

Compugen faces competition from larger pharmaceutical companies with established immuno-oncology therapies. Its competitive advantage lies in its novel target discovery platform and first-in-class therapeutic candidates. The above listed companies may compete in the same market with varying degrees of overlap in specific indications, research areas, or collaborations.

Historical Growth: Historical growth has been driven by licensing agreements and milestone payments, but with high operating costs related to R&D.

Future Projections: Future growth depends on successful clinical trial outcomes and commercialization of pipeline candidates. Analyst estimates would be needed.

Recent Initiatives: Recent initiatives include advancing COM701 and BAY 1905254 through clinical trials and seeking additional partnerships.

Compugen is a clinical-stage immuno-oncology company with a novel target discovery platform. Its strength lies in its innovative pipeline and partnerships. However, it faces risks associated with clinical trial outcomes and competition from established players. Future success depends on progressing its pipeline and securing further partnerships.

Data Sources:

• Compugen Corporate Website
• SEC Filings (10-K, 10-Q)
• Company Presentations
• Analyst Reports (when available)

Disclaimers:

This analysis is based on publicly available information and general market knowledge. It is not financial advice and should not be used as the sole basis for investment decisions. Market share data is estimated.